McKinley Capital Management’s Top Picks Include Apple Inc (AAPL), Facebook Inc (FB) & Gilead Sciences Inc (GILD)

On the second spot is Facebook Inc (NASDAQ:FB), in which McKinley Capital reported a $57.39 million position, which contains 669,137 shares. Facebook Inc (NASDAQ:FB)’s stock has not disappointed investors this year, gaining 20.87%. The latest earnings report showed that the company posted earnings of $0.50 per share and exceeded the estimates by $0.03, while its revenue of $4.04 billion also beat the expectations by $50 million. Lone Pine Capital, led by Stephen Mandel, was the largest shareholder of Facebook Inc (NASDAQ:FB) among the funds we track, ending the first quarter with 8.11 million shares.

Finally, after a 6% cut in its stake, McKinley holds 419,438 shares of Gilead Sciences Inc (NASDAQ:GILD), valued at $49.11 million. Gilead Sciences Inc (NASDAQ:GILD) is a $167.95 billion biopharmaceutical company that discovers, develops and commercializes innovative medicines. On a year-to-date basis the stock has already returned 21.41%, beating its industry peers which on average appreciated by 7.92%. After such a good rally, analysts still see some potential setting a price target with an 11% premium on the stock.  According to our extensive database that covers over 700 hedge funds, Donald Chiboucis’ Columbus Circle Investors is among the top shareholders of Gilead Sciences Inc (NASDAQ:GILD)’s, owning some 4.42 million shares, according to its latest 13F filing for the second quarter.

Disclosure: None.